Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter dialyzers

This article was originally published in The Gray Sheet

Executive Summary

Planned closure of the firm's Ronneby, Sweden and Miami Lakes, Florida plants, which made recently discontinued A-series hemodialyzer components, is announced Nov. 26. The Swedish filter plant and the Florida filter fiber facility employed 158 and 98 people, respectively. A small team will remain at both locations to continue ongoing investigations into more than 50 deaths worldwide that appear linked to a processing fluid residue ("The Gray Sheet" Nov. 12, 2001, p. 16). Baxter has agreed to pay the families of 10 fatalities in Spain $289,000 each under a settlement agreement; the families are asking the Spanish government to drop a planned lawsuit. A Swedish criminal investigation is ongoing...

You may also be interested in...

Autros Acquisition, Guardian Software May Boost Baxter Public Safety Image

Recent patient safety-related measures taken by Baxter International may help improve the firm's public image after a series of recalls and warning letters related to Baxter dialyzers and infusion pumps

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts